Sign In
Buy ALRN
$2.11
+0 (+0%)
At Close: Apr 09, 2025
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
12:00am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
Aileron Therapeutics (ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients
Aileron Communications Announces Promotions
12:00am, Tuesday, 12'th May 2020
Aileron Communications, a strategic communications agency specializing in complex, high-stakes engagements, announced today the promotions of Peter Gr
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
12:30pm, Monday, 11'th May 2020
Aileron Therapeutics (ALRN) today reported business highlights and financial results for the first quarter ended March 31, 2020. “We look forward to announcing interim data from the dose optimizati
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Dynavax (DVAX)
03:50pm, Friday, 01'st May 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN) and Dynavax (DVAX) with
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Dynavax (NASDAQ: DVAX)
03:50pm, Friday, 01'st May 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (
BMRN
–
Research Report
) and Dynavax (
DVAX
–
Research Report
) with bull
Aileron Therapeutics (ALRN) Receives a Buy from H.C. Wainwright
08:14am, Monday, 27'th Apr 2020
H.C. Wainwright analyst Edward White reiterated a Buy rating on Aileron Therapeutics (ALRN) on April 22 and set a price target of $3.00. The company's
Aileron Therapeutics (ALRN) Receives a Buy from H.C. Wainwright
08:14am, Monday, 27'th Apr 2020
H.C. Wainwright analyst
Edward White
reiterated a
Buy
rating on Aileron Therapeutics (
ALRN
–
Research Report
) on April 22 and set a price target of
$3.00
. The company’s shares closed last Frida
William Blair Remains a Buy on Aileron Therapeutics (ALRN)
04:06pm, Friday, 24'th Apr 2020
William Blair analyst Matt Phipps maintained a Buy rating on Aileron Therapeutics (ALRN) on April 22. The company's shares closed last Friday at $0.53.
William Blair Remains a Buy on Aileron Therapeutics (ALRN)
04:06pm, Friday, 24'th Apr 2020
William Blair analyst
Matt Phipps
maintained a
Buy
rating on Aileron Therapeutics (
ALRN
–
Research Report
) on April 22. The company’s shares closed last Friday at $0.53.
According to
TipRanks.co
William Blair Remains a Buy on Incyte (INCY)
04:06pm, Friday, 24'th Apr 2020
In a report issued on April 20, Matt Phipps from William Blair maintained a Buy rating on Incyte (INCY). The company's shares closed last Friday at
William Blair Remains a Buy on Incyte (INCY)
04:06pm, Friday, 24'th Apr 2020
In a report issued on April 20, Matt Phipps from William Blair maintained a Buy rating on Incyte (INCY –
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Zogenix (ZGNX)
04:06pm, Friday, 24'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and Zogenix (ZGNX). Biogen (BIIB) In a report issued on
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB) and Zogenix (NASDAQ: ZGNX)
04:06pm, Friday, 24'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (
BIIB
–
Research Report
) and Zogenix (
ZGNX
–
Research Report
).
Biogen (BIIB)
In a report issued on Apri
Analysts Offer Insights on Healthcare Companies: Tactile Systems Technology (TCMD) and Aileron Therapeutics (ALRN)
10:05am, Thursday, 23'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tactile Systems Technology (TCMD) and Aileron Therapeutics
